Seres Therapeutics Inc (MCRB)

05:25 AM

Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World

05:25 AM

Nov 15, 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Nov 14, 2024

Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres reports Q3 EPS from continuing operations (33c), consensus (24c) - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics expects cash to fund operations into Q4 of 2025 - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics: Q3 Earnings Snapshot - New Haven Register

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics reports Q3 EPS 58c, consensus (24c) - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 07, 2024

Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Nov 07, 2024

Nov 06, 2024

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - The Manila Times

Nov 06, 2024

Nov 06, 2024

Seres Therapeutics Q3 2024 Earnings Call: MCRB Sets Key November Date | MCRB Stock News - StockTitan

Nov 06, 2024

Oct 30, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia

Oct 30, 2024

Oct 30, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock - Investing.com

Oct 29, 2024

Oct 26, 2024

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St

Oct 26, 2024

Oct 24, 2024

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN

Oct 24, 2024

Oct 24, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $5.08 Consensus Price Target from Analysts - MarketBeat

Oct 24, 2024

Oct 24, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat

Oct 24, 2024

Oct 23, 2024

Seres cut to underweight by JP Morgan on Vowst sale - MSN

Oct 23, 2024

Oct 23, 2024

Seres cut to underweight by JP Morgan on Vowst sale (NASDAQ:MCRB) - Seeking Alpha

Oct 23, 2024

Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 21, 2024

Oct 16, 2024

Seres Therapeutics Inc (MCRB)’s stock price range in the last year - US Post News

Oct 16, 2024

Oct 15, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat

Oct 15, 2024

Oct 14, 2024

Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Strong at 0.81, Up 4.77 - The Dwinnex

Oct 14, 2024

Oct 14, 2024

The time has not yet come to remove your chips from the table: Seres Therapeutics Inc (MCRB) - SETE News

Oct 14, 2024

Oct 11, 2024

Introducing Our Rant Against Seres Therapeutics Inc - US Post News

Oct 11, 2024

Oct 10, 2024

Seres Therapeutics gains amid takeover speculation - MSN

Oct 10, 2024

Oct 09, 2024

Seres Therapeutics Inc [MCRB] is -44.91% lower this YTD. Is it still time to buy? - The DBT News

Oct 09, 2024

Oct 09, 2024

An analyst sees good growth prospects for Seres Therapeutics Inc (MCRB) - SETE News

Oct 09, 2024

Oct 08, 2024

Seres Therapeutics Inc (MCRB) Stock: A Year of Declines and Increases - The InvestChronicle

Oct 08, 2024

Oct 08, 2024

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value - Yahoo Finance

Oct 08, 2024

Oct 07, 2024

Is Seres Therapeutics Inc (MCRB) a good investment opportunity? - US Post News

Oct 07, 2024

Oct 07, 2024

Gaining Ground: Seres Therapeutics Inc (MCRB) Closes Higher at 0.85, Up 1.35 - The Dwinnex

Oct 07, 2024

Oct 05, 2024

Nestlé agrees to buy microbiome therapy Vowst from Seres - MSN

Oct 05, 2024

Oct 02, 2024

Seres Therapeutics Inc (MCRB) is looking forward to a strong quarter - SETE News

Oct 02, 2024

Oct 02, 2024

Seres Therapeutics Inc (MCRB) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 02, 2024

Oct 01, 2024

5 Best Microbiome Companies (November 2024) - Securities.io

Oct 01, 2024

Sep 30, 2024

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A - GlobeNewswire

Sep 30, 2024

Sep 30, 2024

Understanding Seres Therapeutics Inc Inc. (MCRB) Price Performance Through Chart Patterns - The InvestChronicle

Sep 30, 2024

Sep 30, 2024

Ratios in Focus: Analyzing Seres Therapeutics Inc (MCRB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 30, 2024